We reiterate our Buy recommendation and raise our target price to NOK 5.0 per share (from NOK 4.0). Since initiating coverage, significant progress has occurred both within the radiopharmaceutical industry and at Thor Medical. Industry momentum remains strong, with a growing number of clinical-stage targeted radiotherapies, including an expanding pipeline of Pb-212–based assets. Several projects, notably those involving Thor Medical’s partners, are now advancing beyond the preclinical stage. Tho ....
